BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

REGN upcoming catalysts

Regeneron Pharmaceuticals: 4 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (1 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 17 readout(s) and 5 FDA event(s). Subscribe to REGN (.ics).

Drugs: Cemiplimab, Fianlimab, Pembrolizumab, REGN7508, REGN9933, Dupilumab, REGN7999, Alirocumab, Apixaban, Platinum-based doublet chemotherapy, Bevacizumab, Trifluridine-tipiracil, Ravulizumab, Eculizumab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Semaglutide

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-03 est.P2Regeneron Pharmaceuticals REGNNCT06421636 A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult ParticipantNon-Transfusion Dependent Beta-Thalassemia (NTDT)active not recruiting19
2026-12-29 est.P2Regeneron Pharmaceuticals REGNNCT07477704 A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have HypercholesterolemiaHypercholesterolemiaactive not recruiting438
2027-01-15 est.P3Regeneron Pharmaceuticals REGNNCT05608291 A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it HasMelanomaactive not recruiting1564
2027-02-09 est.P2Regeneron Pharmaceuticals REGNNCT07175428 Safety in Adult Participants With Atrial Fibrillation Who Are Treated With AnticoagulationAtrial Fibrillation (AF)recruiting1200

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-08-19FDA approvalapprovedREGENERON PHARMACEUTICALS, INC REGNPASATRUApproved 2026-08-19: PASATRU (BLA761508 ORIG1)
2026-04-22FDA approvalapprovedREGENERON PHARMACEUTICALS REGNDUPIXENTApproved 2026-04-22: DUPIXENT (BLA761055 SUPPL74)
2026-04-02FDA approvalapprovedREGENERON PHARMACEUTICALS REGNEYLEA HDApproved 2026-04-02: EYLEA HD (BLA761355 SUPPL5)
2026-02-23FDA approvalapprovedREGENERON PHARMACEUTICALS REGNDUPIXENTApproved 2026-02-23: DUPIXENT (BLA761055 SUPPL75)
2025-11-19FDA approvalapprovedREGENERON PHARMACEUTICALS REGNEYLEA HDApproved 2025-11-19: EYLEA HD (BLA761355 SUPPL10)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-13 est.P2Regeneron Pharmaceuticals REGNNCT07431086 Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the USOverweight or Obesityactive not recruiting120
2026-11-13 est.P1/P2Regeneron Pharmaceuticals REGNNCT04626635 A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced CancersAdvanced Solid Tumorsactive not recruiting548
2026-11-02 est.P2Regeneron Pharmaceuticals REGNNCT06190951 A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 MelanomaMelanomaactive not recruiting151
2026-10-09P3Regeneron Pharmaceuticals REGNNCT02612454 Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)Atopic Dermatitiscompleted880
2026-09-28P3Regeneron Pharmaceuticals REGNNCT05133531 A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNHParoxysmal Nocturnal Hemoglobinuriacompleted202
2026-08-24 est.P2Regeneron Pharmaceuticals REGNNCT06161441 A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in AResectable Non-small Cell Lung Canceractive not recruiting195
2026-07-21P1/P2Regeneron Pharmaceuticals REGNNCT07218770 A Study of REGN7041 for Active Noninfectious Uveitis in Adult ParticipantsActive Noninfectious Uveitis Affecting the Posterior Segmentterminated1
2026-07-09P3Regeneron Pharmaceuticals REGNNCT06548100 A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized LipodystrophGeneralized Lipodystrophycompleted9
2026-06-17P2Regeneron Pharmaceuticals REGNNCT03888105 A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With OtB-cell Non-Hodgkin Lymphoma (B-NHL)active not recruiting515
2026-06-16P2Regeneron Pharmaceuticals REGNNCT06299098 A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for WeigObesitycompleted1005
2026-06-08 est.P2Regeneron Pharmaceuticals REGNNCT06384820 Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous SquCutaneous Squamous Cell Carcinomawithdrawn
2026-05-06P2Regeneron Pharmaceuticals REGNNCT06593600 Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)Postural Orthostatic Tachycardia Syndrome (POTS)completed82
2026-05-02P3Regeneron Pharmaceuticals REGNNCT07309432 Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen AllergyAllergic Conjunctivitisterminated24
2026-03-27P2Regeneron Pharmaceuticals REGNNCT06299111 A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central CatheVenous Thromboembolismcompleted195
2026-03-12P3Regeneron Pharmaceuticals REGNNCT05352672 Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Melanomaactive not recruiting1546
2026-02-23P2Regeneron Pharmaceuticals REGNNCT05831176 A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Eosinophilic Gastritis (EoG); Eosinophilic Duodenitis (EoD); Eosinophilic Gastrointestinal Disease (active not recruiting22
2026-02-01P2Regeneron Pharmaceuticals REGNNCT06608901 A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced HypotensionSepsis-Induced Hypotensioncompleted76

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.